<sup>99m</sup>Tc-1-Thio-D-Glucose in Lymphoma Patients: Safety, Pharmacokinetics and Dosimetric Characteristics

Purpose : To study the safety of 99m Tc-1-Thio-D-Glucose ( Tc-TG) using, as well its pharmacokinetics and dosimetric characteristics. Material methods The 99mTc-TG was studied in 12 patients with lymphomas. performed after a bolus injection 729 ± 102 MBq Tc-TG. Whole body anterior posterior planar imaging at 2, 4, 6, 24 hours post-injection. In addition, all underwent SPECT/CT scanning 2 only SPECT 4 6 injection. determine dynamics Tc-TG accumulation organs tissues, corresponding regions interest (ROI) were outlined on each scans. Absorbed doses calculated using specialized OLINDA/EXM 1.1 program phantoms adult women men. Results showed that administration is tolerated by not accompanied any side effects. specified radiopharmaceutical has favorable properties. Thus, present study, effective ranged from 5.0 to 9.8 mSv. revealed high uptake nodular lesions detected according standard diagnostic methods. There also agreement between visualization extranodal cases brain, neck, chest abdomen lesions. our use allowed us detect bone lesion visualized CT. This finding an indication for additional MRI examination, which confirmed lymphoma humerus. Tc-TG, tumor-background ratio reached 3.3 1.2, then decreased 2.30 1.42 did change significantly, so optimal time performing introduction Conclusion may become method molecular living countries limited or no access PET.